IP Library Granted Patent US 7,235,661
Granted Patent B2
US 7,235,661 · App. 11/395,807 · Granted Jun 26, 2007

Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction

Assignee: Abbott Laboratories
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,235,661
App. No.
11/395,807
Granted
Jun 26, 2007
Kind
B2
Abstract

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B 1 , are as described in the specification.

Claims (41)

1. A compound of formula (II)

or a pharmaceutically acceptable salt, or N-oxide, thereof, wherein

A is selected from the group consisting

V is selected from the group consisting of CR V and N;

R V , is independently selected from the group consisting of hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, —NZ 1 Z 2 , (NZ 3 Z 4 )carbonyl, and (NZ 3 Z 4 )sulfonyl;

R Y is selected from the group consisting of hydrogen, alkenyl, alkoxycarbonyl, alkyl, arylalkyl, and (NZ 3 Z 4 )carbonyl;

Z 1 and Z 2 are each independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, and formyl;

Z 3 and Z 4 are each independently selected from the group consisting of hydrogen, alkyl, aryl, and arylalkyl;

L is alkylene;

D is selected from the group consisting of

 wherein the left end is attached to L and the right end is attached to B 1 ;

R A is selected from the group consisting of hydrogen and alkyl;

Z is N;

--- is absent;

B 1 is selected from the group consisting of

R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, —NZ 1 Z 2 , (NZ 3 Z 4 )carbonyl, and (NZ 3 Z 4 )sulfonyl;

X 1 is selected from the group consisting of N(R 6 ), O and S;

Y 1 is selected from the group consisting of C(R 7 ) and N;

R 6 is selected from the group consisting of hydrogen and alkyl; and

R 7 is selected from the group consisting of hydrogen and alkyl.

2. The compound according to claim 1 wherein

3. The compound according to claim 1 wherein

R Y is selected from the group consisting of hydrogen and alkyl; and

R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, alkoxy, alkyl, alkylthio, cyano, and halogen.

4. The compound according to claim 3 selected from the group consisting of

2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole; and

2-[4-(1H-thieno[3,4-d]imidazol-2-ylmethyl)-1-piperazinyl]nicotinonitrile.

5. The compound according to claim 1 wherein

6. The compound according to claim 5 wherein

R Y is selected from the group consisting of hydrogen and alkyl; and

R 1 , R 2 , R 3 , R 4 , and R 5 are independently selected from the group consisting of hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, and hydroxy.

7. The compound according to claim 6 selected from the group consisting of

2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole;

4-[4-(1H-thieno[3,4-d]imidazol-2-ylmethyl)-1-piperazinyl]phenol; and

2-({4-[2-(methylthio)phenyl]-1-piperazinyl}methyl)-1H-thieno[3,4-d]imidazole.

8. The compound according to claim 1 wherein

9. The compound according to claim 8 wherein

R Y is selected from the group consisting of hydrogen and alkyl; and

R 2 , R 3 , and R 4 are independently selected from the group consisting of hydrogen, alkyl, and halogen.

10. The compound according to claim 9 that is 2-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}-1H-thieno[3,4-d]imidazole.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030176/0968 →
Continuity (3)
Division 1044381400 · May 23, 2003
Provisional Application 6038429100 · May 29, 2002
Related Publication 20060172995A1 · Aug 3, 2006